LANCET Stem cell therapy is being hailed as the next leap forward in urogynaecology after a trial of skeletal muscle stem cells as a treatment for stress urinary incontinence reported a 90% success rate.Researchers treated 42 women with ultrasound-guided injections of autologous myoblasts and fibroblasts, with the aim of promoting muscle regeneration in the rhabdosphincter and reducing urethral atrophy.The treatment was almost 10 times more effective at restoring continence after 12 months compared with injections of collagen, the authors reported in the Lancet (30 June).Myoblasts taken from skeletal muscle have been shown to have the same physiological properties as those from the rhabdosphincter and have adult tissue stem cell potential,” the authors wrote.The authors of an accompanying editorial...
The content on this site is available to Australian Registered Health Practitioners only. Please login or register for access.